Download full-text PDF |
Source |
---|
Arch Dermatol Res
January 2025
Dermatology and Venereology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Morphea is a chronic inflammatory fibrosing disorder. Since fibrosis is the hallmark of both scars and morphea, our attention was raised for the possible use of Fractional Ablative CO lasers and microneedling as treatment modalities for morphea. To compare the efficacy and safety of Fractional Ablative CO lasers and microneedling in the treatment of morphea.
View Article and Find Full Text PDFBackground/aims: Bruise is the extravasation of blood that may be mild or severe. Bone marrow mesenchymal stem cells (BM-MSCs) are one of the most promising cells used in regenerative medicine for treating many disorders. We aimed to evaluate the efficiency of BM-MSCs in treating cutaneous bruises.
View Article and Find Full Text PDFInt Immunopharmacol
January 2025
The Second Affiliated Hospital, Guangdong Provincial Key Laboratory of Allergy & Immunology, The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China. Electronic address:
Objected: Mal f 1, the first allergen cloned from Malassezia furfur, has been found to have positive IgE reactivity in sera from patients with skin inflammation. In vitro, it has also been shown to induce maturation of dendritic cells and release inflammatory factors. However, its role in skin lipid homeostasis remains largely unexplored.
View Article and Find Full Text PDFBr J Dermatol
January 2025
The School of Translational Medicine, Monash University and Alfred Health, Melbourne VIC, Australia.
Background: Epidermolysis bullosa (EB) is a group of rare, severe, genetic disorders characterised by persistent skin fragility and open wounds. EB manifests as cutaneous and mucosal blistering, erosions and impaired wound healing.
Objectives: To determine the long-term efficacy, tolerability and safety of Oleogel-S10 (birch bark extract) in dystrophic (DEB) and junctional (JEB) EB in the 24-months open-label phase (OLP) of the EASE study.
Clin Cancer Res
January 2025
Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Introduction: Elacestrant has shown significantly prolonged progression-free survival compared to standard-of-care endocrine therapy in estrogen receptor-positive (ER-positive), HER2-negative metastatic breast cancer (BC), while potential benefit in early-stage disease requires further exploration. The SOLTI-ELIPSE window-of-opportunity trial investigated the biological changes induced by a short course of preoperative elacestrant in postmenopausal women with early BC.
Methods: Eligible patients with untreated T1c (≥1.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!